Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Moodys
Mallinckrodt
McKinsey
Harvard Business School

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drug Sales Trends for SUMAVEL DOSE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Drug Sales Revenue Trends for SUMAVEL DOSE
Drug Units Sold Trends for SUMAVEL DOSE

Annual Sales Revenues and Units Sold for SUMAVEL DOSE

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
SUMAVEL DOSE   Start Trial   Start Trial 2017
SUMAVEL DOSE   Start Trial   Start Trial 2016
SUMAVEL DOSE   Start Trial   Start Trial 2015
SUMAVEL DOSE   Start Trial   Start Trial 2014
SUMAVEL DOSE   Start Trial   Start Trial 2013
>Drug Name >Revenues (USD) >Units >Year

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
McKesson
Colorcon
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.